Oleander
Differential Activities of the Botanical Extract PBI-05204 and Oleandrin on Innate Immune Functions under Viral Challenge Versus Inflammatory Culture Conditions
The Nerium oleander extract PBI 05204 (PBI) and its cardiac glycoside constituent oleandrin have direct anti-viral properties. Their effect on the immune[read more]
Discovery of senolytics using machine learning
Cellular senescence is a stress response involved in ageing and diverse disease processes including cancer,[read more]
Jun
The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo
Treatment of rhabdomyosarcoma (RMS), the most common a soft tissue sarcoma in childhood, provides intensive[read more]
Dec
Suppression of the ‘stemness’ of glioblastoma stem cells
Glioblastoma multiforme (GBM) is an aggressive form of primary brain neoplasm that has a poor[read more]
Jun
Antitumor effects of oleandrin in different types of cancers: Systematic review
This article encourages future studies to verify the applicability of oleandrin in antineoplastic therapeutic protocols,[read more]
Jun
Efficacy of oleandrin and PBI-05204 against bovine viruses of importance to commercial cattle health
Bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), and bovine coronavirus (BCV) threaten[read more]
May
A Role for Cardiac Glycosides in GBM Therapy
Abstract There is a pressing need for new effective therapeutic strategies to treat glioblastoma (GBM). Cardiac[read more]
Apr
Feb
“Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1”
Yong L, Ma Y, et al. Phtyother. Res. 2019 May. This article shows that oleandrin[read more]
May
“Oleandrin and its derivative Odoroside A, both cardiac glycosides, exhibit anticancer effects by inhibiting invasion via suppressing the STAT-3 signaling pathway”.
Intnl. J. Mol. Sci. 2018, 19(11); 3350. Ko YS, Rugira T, Jin H, Park SW[read more]
May
HTLV-1.
HTLV stands for Human T-cell Leukemia Virus. It is a retrovirus that infects a type[read more]
Mar
Dec
The U.S. Army Medical Research Institute together with Dr. R. Newman (PBI Chief Science Officer) presented research with PBI’s oleander extract at the 9th International Symposium on Filoviruses held in Marburg, Germany.
The data presented showed highly significant inhibition of Ebola virus. Research is ongoing with respect[read more]
Sep
Apr
Because the active principle ingredient in PBI-05204 readily crosses the blood brain barrier (BBB) it has the potential to benefit malignant disease that resides in the brain.
PBI has initiated research on pediatric glioblastoma multiforma (GBM) together with Dr. Xiao-Nan Li (Brain[read more]
Jan
PBI is extremely pleased to announce an expansion of their Scientific Advisory Board to include world class experts in antiviral, neurodegenerative disease and cancer related research fields.
Please see the SAB tab on this web page to view current SAB members, institutional[read more]
Jan
PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer.
This disease is often diagnosed only after it has metastasized throughout the body making any[read more]
Dec
Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer
by: Jasem Al Shemaili, Khatija Parekh, Robert Newman, Björn Hellman, Carl Woodward, Abdu Adem, Peter[read more]
Jun
PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.
To date, 37 patients of the target goal of 50 have been entered on the[read more]
Apr
Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.
Not only have our two published studies shown an increase in brain derived neurotrophic factor[read more]
Sep
Presentation Abstract: PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits the growth of human pancreatic cancer in a Panc-1 orthotopic model by down-regulation of PI3k/mTOR pathways.
Dr. Robert A. Newman, our Chief Science Officer will be presenting at the Beaujon Conference[read more]
Jan
Presentation Abstract: PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits the growth of human pancreatic cancer in a Panc-1 orthotopic model by down-regulation of PI3k/mTOR pathways.
Yong Pan, Sun-Jin Kim, Patrea Rhea, Carrie Cartwright, Ho Jeong Lee, Crandell Addington, Mihai Gagea,[read more]
Apr
Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity.
Singh S, Shenoy S, Nehete PN, Yang P, Nehete B, Fontenot D, Yang G, Newman[read more]
Nov
Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes.
Campia I, Sala V, Kopecka J, Leo C, Mitro N, Costamagna C, Caruso D, Pescarmona[read more]
Oct
Cellular location and expression of Na+, K+-ATPase α subunits affect the anti-proliferative activity of oleandrin.
Yang, P., Cartwright, C., Efuet, E., Hamilton, S. R., Wistuba, I. I., Menter, D., Addington,[read more]
Oct
Research Article: Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.
Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala[read more]
Jul
Publication: In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models.
Dunn DE, He DN, Yang P, Johansen M, Newman RA, Lo DC. J Neurochem. 2011[read more]
Nov

ASCO annual meeting poster presentation along with an oral format with discussion of clinical trial results of PBI-05204.
READ MORE[read more]
Jun
Publication: Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunits.
Lin Y, Ho DH, Newman RA. J Exp Ther Oncol. 2010;8(4):271-86. PMID: 21222360[read more]
Jun
Phoenix Biotechnology executes a third amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.
Publication: Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug[read more]
Aug
May
Phoenix Biotechnology executes a second amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.
Publication: Determinants of human and mouse melanoma cell sensitivities to oleandrin. Lin Y, Dubinsky WP,[read more]
Sep
Feb
Technology Accelerator Initiative.
Phoenix Biotechnology is designated a "Super Star" by the San Antonio Technology Accelerator Initiative.[read more]
Jan